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Abstract
Background: Heroin is a synthetic opioid with an extensive illicit market leading to large numbers
of people becoming addicted. Heroin users often present to community treatment services
requesting detoxification and in the UK various agents are used to control symptoms of
withdrawal. Dissatisfaction with methadone detoxification [8] has lead to the use of clonidine,
lofexidine, buprenorphine and dihydrocodeine; however, there remains limited evaluative research.
In Leeds, a city of 700,000 people in the North of England, dihydrocodeine is the detoxification
agent of choice. Sublingual buprenorphine, however, is being introduced. The comparative value of
these two drugs for helping people successfully and comfortably withdraw from heroin has never
been compared in a randomised trial. Additionally, there is a paucity of research evaluating
interventions among drug users in the primary care setting. This study seeks to address this by
randomising drug users presenting in primary care to receive either dihydrocodeine or
buprenorphine.
Methods/design: The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) project is a
pragmatic randomised trial which will compare the open use of buprenorphine with
dihydrocodeine for illicit opiate detoxification, in the UK primary care setting. The LEEDS project
will involve consenting adults and will be run in specialist general practice surgeries throughout
Leeds. The primary outcome will be the results of a urine opiate screening at the end of the
detoxification regimen. Adverse effects and limited data to three and six months will be acquired.
Published: 29 April 2004
BMC Family Practice 2004, 5:9
Received: 10 April 2003
Accepted: 29 April 2004
This article is available from: http://www.biomedcentral.com/1471-2296/5/9
© 2004 Oldham et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all 
media for any purpose, provided this notice is preserved along with the article's original URL.BMC Family Practice 2004, 5 http://www.biomedcentral.com/1471-2296/5/9
Page 2 of 7
(page number not for citation purposes)
Background
Heroin is a synthetic opioid and a 'Class A' controlled
drug [14]. As such, in the United Kingdom, there has been
an extensive illicit market for the sale of the drug, leading
to large numbers of people becoming addicted. It is diffi-
cult however, to give precise figures of how many people
are dependent on heroin in the UK as there has never been
a national survey of the prevalence of drug misuse [4].
Official statistics, however, record those presenting to
treatment. Most recent figures from Regional Drug Misuse
Databases show that in the six months ending March
1998, 30,000 people in Great Britain presented to drug
treatment services [5]. The UK Home Office Addict Noti-
fication System (stopped May 1997) showed a doubling
of the number of addicts who approached the treatment
system over the six years 1990–1996. The number of drug
users notified in 1996 was 43,372 (over 90% of which
were notifications for heroin or methadone) [6]. Though
possession of the drug is illegal under the Misuse of Drugs
Act 1971, there is an extensive range of both statutory and
non-statutory services that aim to provide treatment to
those who are heroin dependent. This reflects the tradi-
tion in the UK that there have been minimal restrictions
placed on doctors wishing to prescribe for drug
dependence.
As well as placing a large burden on both health and other
services, heroin dependency is dangerous to individual
users and society. There were 2,300 drug-related deaths
identified in England and Wales in 1998 due to accidental
or intentional overdose and there is a rising trend. A
young person who is injecting heroin has about a 14 times
higher risk of death than someone who is not.[1]. There is
an exponential relationship between the likelihood of
being drug dependent and living in a deprived commu-
nity.[12]. At least one third of all individuals in contact
with probation services are drug misusers.[19].
Drug users often present to community treatment services
requesting detoxification from heroin. In the UK, various
therapeutic agents are used to control symptoms of street
opiate withdrawal. Neither national guidelines, nor
indeed the evidence base behind rapid detoxification
from opiates give a 'drug of choice' for successful rapid
detoxification. In the UK, the most commonly used drug
has been methadone, employing incremental reductions
in the dose over 7–21 days [19]. Dissatisfaction with
methadone stems from the fact that it has a long-half life
[16,8]. Therefore, though dose reductions are relatively
easy to achieve in the initial phase of detoxification pro-
gramme, patients report distressing withdrawal symptoms
in the latter stages.
This has lead to the use of alternative detoxification agents
such as clonidine, lofexidine, buprenorphine and dihy-
drocodeine. Clonidine has been used extensively, but its
pronounced hypotensive and sedative effects have now
rendered it unsuitable for community detoxification and
its use has been superseded by the analogues lofexidine
[16], and guanfacine (not used in the UK). Although the
hypotensive effects of lofexidine are less than clonidine,
its high cost and reduced ability to control the withdrawal
effects compared to a substitute opiate [17,15] have
resulted in limited clinical uptake. Lofexidine tends to be
the treatment of choice for the minority of people who are
going straight to opiate-antagonist (naltrexone) relapse
prevention medication. Dihydrocodeine is attractive to
clinicians as it has a shorter half-life than methadone,
seems equally acceptable to users, and is less open to
abuse by injecting than methadone tablets. Buprenor-
phine, in the form of sub-lingual tablets, has already been
used in clinical situations for opiate detoxification (street
heroin or prescribed opiates) [13], but is relatively new for
this purpose in the UK. There has only been one pub-
lished randomised control trial comparing methadone
with buprenorphine [2]. Firm conclusions could not be
drawn due to small numbers and low completion rates in
both groups. There are no published trials comparing the
effectiveness of buprenorphine versus lofexidine for opi-
ate withdrawal in drug using populations. Buprenorphine
has the advantage of having a good safety profile, better
retention in treatment and lower withdrawal severity
compared to clonidine [10,11,3,7]. As a result, it is likely
to become widely used in the UK.
Sublingual buprenorphine has been compared with dihy-
drocodeine for postoperative pain [9], but never, in a ran-
domised trial, for opiate detoxification (street heroin or
prescribed opiates). In the UK there is a narrow window
of opportunity to undertake an evaluative study.
Aim
To evaluate whether buprenorphine or dihydrocodeine,
given openly to moderately severe users of street opiates
presenting for detoxification in the NHS primary care set-
ting, helps achieve abstinence at completion of a reducing
regimen.
To record primary and secondary outcomes at completion
of the reducing regime and at tertiary outcomes at three
and six month intervals.
Methods
Setting
As many short-term detoxification programmes are
undertaken outside of specialist services, the Leeds Evalu-
ation of Efficacy of Detoxification Study (LEEDS) project
will evaluate the open use of buprenorphine versus dihy-
drocodeine in the UK primary care setting. The LEEDS
project is intended to complement rather than competeBMC Family Practice 2004, 5 http://www.biomedcentral.com/1471-2296/5/9
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with research taking place in secondary care. Much of the
current evidence base for pharmacological treatment of
drug use comes from studies that have taken place in an
in-patient or residential setting. There is an urgent need to
verify whether such research is applicable to a community
and primary care environment. The ethos of the study will
be a collaborative project between primary care and the
secondary care, academic departments and service provid-
ers. Information is produced for General Practitioners
thinking of taking part in the LEEDS project (Additional
file 1).
Leeds is an industrial city and financial centre of 700,000
people in the North of England.
Randomisation
Randomisation will be by random block size, stratified by
practice. It will be undertaken centrally in the Academic
Department of Psychiatry and Behavioural Sciences, Uni-
versity of Leeds and not by the primary care teams them-
selves. Microsoft Excel 'RAND' function will be used to
choose two even numbered block sizes less than ten.
Again, using the function in MS Excel, the order of use of
these block sizes will be randomised. Which drug regimen
is represented by which numbers within the block is then
selected, again at random. Finally a table of random num-
bers will be used to randomise the order of drugs within
the blocks.
Opaque consecutively numbered envelopes will be pre-
pared for each practice. If a patient is both eligible and
consents to the trial, the next envelope will be opened by
the prescribing doctor and the intervention allocated. The
envelopes will be used in numerical order so as not to
interfere with the randomisation process.
Pragmatic design
The design of the study is to suit the logistics of everyday
general practice. Open dosing and giving regimes exist
whereby the GP, Addiction Therapist and patients know
exactly which opiate detoxification regime they will
follow.
Sample size
Currently no relevant randomised controlled trials exist. It
is therefore problematic to estimate the desired sample
size. With the practices currently working in the LEEDS
project, it is realistic to estimate that we will be able to
accrue 120 people. The sample size will limit the power of
the study. Power calculations were undertaken using Sam-
ple Power 1.20 developed by SPSS Inc., comparing two
groups (60 individuals in each) and for α = 0.05 (two-
sided), (Table 1).
We estimate the proportion of people who successfully
detoxify on dihydrocodeine to be 50–60%. Should there
be a 20% difference in the groups this would give the
LEEDS project 60% power. We recognise that this is
somewhat low but this power calculation is based on a
series of assumptions for which we can find little hard evi-
dence. We have also tried to be realistic about accrual, and
the LEEDS project will evaluate locally relevant treatments
and will, at the very least, provide data so that the next
study in this area can be better informed.
Eligibility criteria
A person is eligible if:
- aged 18 years or over
- using street opiates as confirmed by heroin metabolites
in a urine sample taken at first assessment.
- stating that the level of opiate use is moderate (as detoxi-
fication needs to be completed within a three week time
period), that is
❍  heroin – not more than ~£20/day injecting – currently
this means between 0.4 and 0.7 g/day, or £30/day smok-
ing or
❍  methadone mixture – use of no more than 30 mg (30
ml)/day
Table 1: Power calculations for sample of 120
Difference between groups Power
70% × 60% 21%
70% × 50% 61%
70% × 45% 80%
70% × 40% 92%
60% × 50% 20%
60% × 40% 59%
60% × 35% 79%
60% × 30% 92%
50% × 40% 20%
50% × 30% 61%
50% × 25% 82%
40% × 30% 21%
40% × 20% 67%
40% × 15% 88%
30% × 20% 24%
30% × 15% 50%
30% × 10% 79%
20% × 15% 11%
20% × 10% 33%
20% × 5% 70%BMC Family Practice 2004, 5 http://www.biomedcentral.com/1471-2296/5/9
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- expressing a wish to detoxify through the standard mon-
itored process and remain abstinent from opiates.
- willing to give informed consent (Additional file 2) after
receiving the patient information leaflet (Additional file
3)
- No contra-indications to dihydrocodeine or
buprenorphine
❍  Registered at one of the 50 General Practices that form
part of the Leeds Shared Care scheme for the management
of drug users.
Specifically, polydrug use (e.g. dependence to other sub-
stances such as alcohol, benzodiazepines or stimulants)
will not be excluded from the trial.
On giving consent
The treatment option will be concealed from both patient
and clinician at the time of the eligibility assessment. Both
parties will remain blind to the treatment to be prescribed
until the envelope is opened.
The General Practitioner will complete the outside of the
allocation envelope before it is opened, recording the per-
son's unique identifier number, date of birth, date first
prescription given and an estimate of severity of addiction
and prognosis (see Table 2: Additional file: 5). Adding a
rating tool for severity was considered. This would have
added complexity and made the study less attractive to
busy practitioners. Also, in this pragmatic study, the pur-
pose of the rating was not to be an objective measure of
severity. Rather it was to ensure that the randomisation
had resulted in equal numbers of similarly rated people
entering each group. Even if the external validity is debat-
able this technique should ensure that the reader of the
final report is reassured that randomisation was
successful.
Interventions
1. Dihydrocodeine, given openly, in the context of the
standard General Practitioner/Drugs Therapist support. In
the UK treatment setting, dihydrocodeine cannot be pre-
scribed on FP10 MDA prescriptions. Therefore it is not
possible to offer daily pick-up or supervised dispensing of
the medication.
There is no evidence base to advise the most effective
length of reducing regimen in achieving abstinence. Com-
mon reducing regimens vary between 4 and 14 days.
Therefore the reducing regimen of dihydrocodeine will be
at the discretion of the prescribing doctor and within the
standard regimen shown in table 3. What, therefore, is
being randomised, is not so much a specific dosing regi-
men of dihydrocodeine, but rather the complete package
of care.
2. Buprenorphine, given openly, in the context of the
standard General Practitioner/Drugs Therapist support.
Buprenorphine will be prescribed on an FP10MDA pre-
scription and will therefore be dispensed daily under
supervision.
Table 3: Dihydrocodeine detoxification
Day Number of 30 mg 
tablets
Morning Midday Evening Night-time
1 1 8 5445
2 2 0 5555
3 1 8 5445
4 1 6 4444
5 1 4 4334
6 1 2 3333
7 1 0 3223
892223
982222
1 0 72122
1 1 62112
1 2 51112
1 3 41111
1 4 311 1
15 2 1 1BMC Family Practice 2004, 5 http://www.biomedcentral.com/1471-2296/5/9
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There is no evidence base to advise the most effective
length of reducing regimen in achieving abstinence. Com-
mon reducing regimens vary between 4 and 14 days.
Therefore the reducing regimen of buprenorphine will be
at the discretion of the prescribing doctor and within the
standard regimen shown in table 4. Again it is the open
giving of the regimen of buprenorphine that is being eval-
uated, not identical or similar patterns of giving two
drugs. This is designed to reflect the real world of primary
care rather than more prescriptive environments.
As all sites form part of the city-wide shared care scheme,
ancillary Drugs Therapist support will be standardised
across all sites. The therapists have all received identical
training regarding the trial. This involves the need to offer
identical motivational enhancement for those undergoing
detoxification, regardless of which pharmacological inter-
vention is prescribed.
Data procedures and collection
The initial assessment data, on the randomisation enve-
lope, is posted to the LEEDS project co-ordinator. A
stamped addressed envelope is enclosed within the ran-
domisation envelope. Information is then collated on a
transcription form (Additional file 4) and additional
information sought in the patients' primary care notes
regarding history and use of opiates. LEEDS project
number and details of allocated treatment are also
returned to the Academic Department of Psychiatry and
Behavioural Sciences, University of Leeds, where ran-
domisation was undertaken and where randomisation
codes are kept, to ensure that the correct order of alloca-
tion is being followed.
The primary outcome is abstinence from street opiates at
receiving the final prescription as indicated by a urine test
free of illicit opiates or their metabolites (namely heroin,
monoacetylmorphine, morphine or codeine)*. Whilst the
ideal is that the patient would return for a urine sample
the day after completing the detoxification programme,
this is not feasible given the high rate of non-attendance
by this client group. Failure to complete the course of pre-
scribed detoxification medication, saying that they had
used street opiates, failure to attend appointments to col-
lect repeat prescriptions, refusal to provide a urine sample
on receipt of final prescription or providing a urine sam-
ple that tests positive for opiates on receipt of final pre-
scription will all be counted as unsuccessful
detoxification. The authors recognise that dihydrocodeine
or buprenorphine in the final urine sample indicates that
the user is not opiate free. However the urine sample at
receipt of final script is an attempt to record a feasible out-
come of interest to people working in primary care and
recipients of the detox regimens. Whilst an ideal would be
a urine drug sample taken during the detoxification and
then five days post-detoxification, this is not considered
to be feasible in the primary care setting. Ideally severity
of withdrawal symptoms during the detoxification would
be monitored using a validated research tool. However
this would not be feasible in the multi-site pragmatic set-
ting of primary care.
*An immunoassay for opiates followed by thin layer chro-
matography and in equivocal cases also gas chromatogra-
phy mass spectrometry (GC Mass Spec) for the specific
opiate. This technique allows heroin and its metabolites
to be differentiated from dihydrocodeine and buprenor-
phine and their breakdown products.
Table 4: Buprenorphine detoxification
Day Dose (mg)
16
28
38
46
56
64
73 . 6
83 . 2
92 . 8
10 2.4
11 2.0
12 1.6
13 1.2
14 0.8
15 0.4
Table 5: Dummy table for abstinence from street heroin at final prescription as indicated by urine test
Abstinence successful Abstinence not successful Totals
Buprenorphine A C A+C
Dihydrocodeine B D B+D
Totals A+B C+D A+B+C+D
RR XX 95% CI XX-XX, NNT XX 95% CI XX-XXBMC Family Practice 2004, 5 http://www.biomedcentral.com/1471-2296/5/9
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Practitioners will, as normal, also record details of any sig-
nificant adverse effects. The individual notes of each study
participant will be scrutinised by the LEEDS project co-
ordinator and adverse effects clearly resulting in what
seemed to be clinically significant distress will be
recorded. Additional information on the inappropriate
use of prescribed medication (e.g. intentional overdose),
presentation at Accident and Emergency Departments and
admission to hospital will also be recorded.
The project team recognise the difficulty in tracking peo-
ple with drug problems across a longer period than two to
three weeks. However, attempts will be made to record
abstinence from opiates, employment, and service utilisa-
tion at three and six month intervals after completion of
the allocated detoxification regimen. If possible, this data
will be extracted from patient notes/records. Service utili-
sation, such as presentation at Accident and Emergency
departments, is routinely recorded. Participants will also
be asked to provide a contact telephone number (includ-
ing mobile and/or next of kin) for the purpose of the
project co-ordinator contacting them at the three and six
month follow up stage.
All data for the LEEDS project will be collated from the
LEEDS envelopes and from routine GP/Addiction Thera-
pists notes. Data will be transferred from the transcription
forms onto specially created forms using the Microsoft
Access Database.
Analysis
Analysis will take place within this package and SPSS.
Dummy tables for this analysis are prepared before
recruitment of the first patient (Table 5).
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